Literature DB >> 3987790

Generalization of distribution--free confidence intervals for bioavailability ratios.

V W Steinijans, E Diletti.   

Abstract

The confidence interval approach to bioavailability assessment depends first on selection of the confidence level, usually 95%, and then determination of the confidence limits for the expected bioavailability ratio AUC(Test)/AUC(Reference). In practice, however, it is sometimes of greater interest to know the probability that the expected bioavailability will fall below a critical value, for example 0.75, or within a clinically set bioequivalence range, for example 0.80 to 1.25. Up to now, posterior probability distributions have been suggested, based on classical analysis of variance (ANOVA) with its rather restrictive assumptions, including that of a (logarithmic) normal distribution. In this report, a distribution-free confidence interval based on the Wilcoxon signed-rank statistic has been generalized so that confidence probabilities can be obtained for any given confidence limits. In the case of unimodal and almost symmetrical sampling distributions, the results obtained are very similar to those of the ANOVA-based posterior probability distribution. However, skewed or multimodal sampling distributions are better reflected by the proposed distribution-free method, and more valid information is obtained in these cases, as demonstrated by examples.

Mesh:

Substances:

Year:  1985        PMID: 3987790     DOI: 10.1007/bf00635713

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Digoxin bioavailability: evaluation of a generic tablet and proposed FDA guidelines.

Authors:  W G Kramer; A J Kolibash; M S Bathala; J A Visconti; R P Lewis; R H Reuning
Journal:  J Pharm Sci       Date:  1977-12       Impact factor: 3.534

2.  Bayesian approach to bioequivalence assessment: an example.

Authors:  H Fluehler; A P Grieve; D Mandallaz; J Mau; H A Moser
Journal:  J Pharm Sci       Date:  1983-10       Impact factor: 3.534

3.  Mini-computer programs for bioequivalence testing of pharmaceutical drug formulations in two-way cross-over studies. Including a survey of current parametric evaluation techniques.

Authors:  H P Wijnand; C J Timmer
Journal:  Comput Programs Biomed       Date:  1983 Aug-Oct

4.  Comparison of different methods for decision-making in bioequivalence assessment.

Authors:  D Mandallaz; J Mau
Journal:  Biometrics       Date:  1981-06       Impact factor: 2.571

5.  Statistical analysis of bioavailability studies: parametric and nonparametric confidence intervals.

Authors:  V W Steinijans; E Diletti
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  An aid to decision-making in bioequivalence assessment.

Authors:  H Fluehler; J Hirtz; H A Moser
Journal:  J Pharmacokinet Biopharm       Date:  1981-04
  6 in total
  6 in total

1.  Pharmacokinetics of 4' epi-adriamycin after morning and afternoon intravenous administration.

Authors:  S Eksborg; U Stendahl; K Antila
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

2.  The bioavailability of three altretamine formulations.

Authors:  E A Runhaar; J P Neijt; J J Holthuis; D de Vos
Journal:  Pharm Weekbl Sci       Date:  1989-12-15

3.  Prolongation of the PQ interval as a measure of therapeutic inequivalence between two formulations of diltiazem.

Authors:  O E Della Paschoa; V Luckow; D Trenk; E Jähnchen; S R Santos
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  A non-parametric confidence interval method.

Authors:  A Racine-Poon; A P Grieve
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol.

Authors:  H Malonne; B Sonet; B Streel; S Lebrun; S De Niet; A Sereno; F Vanderbist
Journal:  Br J Clin Pharmacol       Date:  2004-03       Impact factor: 4.335

6.  Carvedilol increases the systemic bioavailability of oral digoxin.

Authors:  C De Mey; E Brendel; D Enterling
Journal:  Br J Clin Pharmacol       Date:  1990-04       Impact factor: 4.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.